Peptide Information

General Information of This Peptide
Peptide ID
PEP00139
Peptide Name
Angiopep-2/TAT
Structure
Sequence
TFFYGGSRGKRNNFKTEEYGRKKRRQRRRPPQQ
Peptide Type
Linear
Receptor Name
Prolow-density lipoprotein receptor-related protein 1 (LRP1)
  Receptor Info 
PDC Transmembrane Types Cell targeting peptides (CTPs); Cell-penetrating peptides (CPPs)
Formula
C179H286N66O48
Isosmiles
[H]NCCCC[C@H](NC(=O)CNC(=O)[C@H](CCC/N=C(/N)N[H])NC(=O)[C@H](CO[H])NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(O[H])cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@]([H])(N[H])[C@@H](C)O[H])C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](CC(=O)N[H])C(=O)N[C@@H](CC(=O)N[H])C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN[H])C(=O)N[C@]([H])(C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O[H])cc1)C(=O)NCC(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](CCCCN[H])C(=O)N[C@@H](CCCCN[H])C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](CCC(=O)N[H])C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N[C@@H](CCC/N=C(/N)N[H])C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N[H])C(=O)N[C@@H](CCC(=O)N[H])C(=O)O)[C@@H](C)O[H]
InChI
InChI=1S/C179H286N66O48/c1-94(247)141(189)167(288)242-124(84-98-34-10-5-11-35-98)162(283)238-123(83-97-32-8-4-9-33-97)161(282)237-121(86-100-52-56-102(250)57-53-100)144(265)215-89-135(256)214-90-136(257)220-127(93-246)165(286)221-103(40-20-72-206-172(190)191)143(264)216-91-137(258)218-104(36-12-16-68-180)146(267)224-113(46-26-78-212-178(202)203)154(275)240-125(87-133(187)254)164(285)241-126(88-134(188)255)163(284)239-122(82-96-30-6-3-7-31-96)160(281)229-108(39-15-19-71-183)159(280)243-142(95(2)248)168(289)233-117(62-67-140(262)263)156(277)231-116(61-66-139(260)261)158(279)236-120(85-99-50-54-101(249)55-51-99)145(266)217-92-138(259)219-105(41-21-73-207-173(192)193)147(268)222-106(37-13-17-69-181)148(269)223-107(38-14-18-70-182)149(270)225-109(42-22-74-208-174(194)195)150(271)226-111(44-24-76-210-176(198)199)152(273)230-114(58-63-130(184)251)155(276)228-110(43-23-75-209-175(196)197)151(272)227-112(45-25-77-211-177(200)201)153(274)234-118(47-27-79-213-179(204)205)169(290)245-81-29-49-129(245)170(291)244-80-28-48-128(244)166(287)232-115(59-64-131(185)252)157(278)235-119(171(292)293)60-65-132(186)253/h3-11,30-35,50-57,94-95,103-129,141-142,246-250H,12-29,36-49,58-93,180-183,189H2,1-2H3,(H2,184,251)(H2,185,252)(H2,186,253)(H2,187,254)(H2,188,255)(H,214,256)(H,215,265)(H,216,264)(H,217,266)(H,218,258)(H,219,259)(H,220,257)(H,221,286)(H,222,268)(H,223,269)(H,224,267)(H,225,270)(H,226,271)(H,227,272)(H,228,276)(H,229,281)(H,230,273)(H,231,277)(H,232,287)(H,233,289)(H,234,274)(H,235,278)(H,236,279)(H,237,282)(H,238,283)(H,239,284)(H,240,275)(H,241,285)(H,242,288)(H,243,280)(H,260,261)(H,262,263)(H,292,293)(H4,190,191,206)(H4,192,193,207)(H4,194,195,208)(H4,196,197,209)(H4,198,199,210)(H4,200,201,211)(H4,202,203,212)(H4,204,205,213)/t94-,95-,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113+,114+,115+,116+,117+,118+,119+,120+,121+,122+,123+,124+,125+,126+,127+,128+,129+,141+,142+/m1/s1
InChIKey
WPTANFPVHYMWOY-KDPNVCHYSA-N
Pharmaceutical Properties
Molecule Weight
4130.671
Polar area
1987.42
Complexity
4128.196745
xlogp Value
-25.9498
Heavy Count
293
Rot Bonds
153
Hbond acc
58
Hbond Donor
64
Each Peptide-drug Conjugate Related to This Peptide
Full Information of The Activity Data of The PDC(s) Related to This Peptide
ANG-TAT-PTX [Investigative]
 PDC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Central nervous system disease
Efficacy Data Inhinition rate
31.65 ± 3.28%
Administration Time 24 h
In Vitro Model Glioblastoma U87 cell CVCL_3429
Experiment 2 Reporting the Activity Data of This PDC [1]
Indication Central nervous system disease
Efficacy Data Inhinition rate
73.53 ± 6.45%
Administration Time 48 h
In Vitro Model Glioblastoma U87 cell CVCL_3429
References
Ref 1 Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget. 2016 Nov 29;7(48):79401-79407. doi: 10.18632/oncotarget.12708.